The Motley Fool
22 May 2026, 21:30 UTC · 17w ago
Verdict
Headline takes no side. We score RLAY +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Relay Therapeutics reported phase 2 trial data for zovegalisib showing a volumetric response in approximately 60% of patients with vascular anomalies.
More positive than 93% of claims this week
Zovegalisib has received FDA breakthrough therapy designation for PIK3CA-mutant HR+/HER2- advanced breast cancer, with a median progression-free survival of 11.1 months.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 86% of claims this week
Relay Therapeutics maintains a strong liquidity position with approximately $642 million in cash and cash equivalents.
So whatHigh cash reserves reduce the immediate risk of dilutive financing or bankruptcy, a primary risk for pre-revenue biotech firms.
More positive than 64% of claims this week
The company is on track to initiate a pivotal phase 3 frontline trial for a combination study involving zovegalisib in early 2027.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company announced promising phase 2 trial data for zovegalisib and has a strong cash position.
More positive than 47% of ticker scores this week
Mentioned as a collaborator in a clinical study, providing a neutral to slightly positive operational context.
More positive than 57% of relationship scores this week
[mutual] Pfizer and Relay Therapeutics entered into a clinical collaboration for a triplet combination study.
More positive than 36% of relationship scores this week
[a_to_b] Pfizer is supplying the CDK4 inhibitor atirmociclib to Relay Therapeutics for a clinical combination study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
3h ago
+33.3%
Price agrees with the score
$18.03 vs $13.53 close before publication (May 22) · not market-adjusted
RLAY chart →
